196 related articles for article (PubMed ID: 36610740)
1. Just DOAC: Use of direct-acting oral anticoagulants in pediatrics.
Mills K; Hill C; King M; Pauley JL; Cober MP; Fenn NE; Omecene NE; Smith T; Sierra CM
Am J Health Syst Pharm; 2023 Mar; 80(7):412-422. PubMed ID: 36610740
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Rollins BM; Silva MA; Donovan JL; Kanaan AO
Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
[TBL] [Abstract][Full Text] [Related]
3. Direct oral anticoagulants versus standard anticoagulation in children treated for acute venous thromboembolism.
Chen J; Bi G; Wu F; Qin X
Pediatr Res; 2023 May; 93(6):1491-1498. PubMed ID: 36071237
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism.
Coons JC; Albert L; Bejjani A; Iasella CJ
Pharmacotherapy; 2020 Mar; 40(3):204-210. PubMed ID: 31968126
[TBL] [Abstract][Full Text] [Related]
5. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
[TBL] [Abstract][Full Text] [Related]
6. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.
van Es N; Coppens M; Schulman S; Middeldorp S; Büller HR
Blood; 2014 Sep; 124(12):1968-75. PubMed ID: 24963045
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.
Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE
Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of direct oral anticoagulants in the pediatric population: a systematic review and a meta-analysis.
Giossi R; Menichelli D; D'Amico F; Idotta L; Cirino M; Scardoni L; Furlanetto C; Maggi M; Bernocchi O; Bosca F; Girlando L; Pignatelli P; Pani A; Pastori D; Tozzo A; Scaglione F; Fornasari D
J Thromb Haemost; 2023 Oct; 21(10):2784-2796. PubMed ID: 37481075
[TBL] [Abstract][Full Text] [Related]
9. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
Voigtlaender M; Langer F
Hamostaseologie; 2017 Oct; 37(4):241-255. PubMed ID: 28508916
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
Perales IJ; San Agustin K; DeAngelo J; Campbell AM
Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
[No Abstract] [Full Text] [Related]
11. Evaluation of Direct-Acting Oral Anticoagulant Use in Patients With Cancer.
Davis DO; Davis KA
J Pharm Pract; 2018 Oct; 31(5):441-444. PubMed ID: 28803521
[TBL] [Abstract][Full Text] [Related]
12. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT; Hamilton M; Bird A; Mitchell SA; Li S; Horblyuk R; Batson S
PLoS One; 2016; 11(8):e0160064. PubMed ID: 27487187
[TBL] [Abstract][Full Text] [Related]
14. Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism.
Paik J
Paediatr Drugs; 2022 Jul; 24(4):423-431. PubMed ID: 35699915
[TBL] [Abstract][Full Text] [Related]
15. A Prospective Cohort Comparative Study of Rivaroxaban, Dabigatran, and Apixaban Oral Thromboprophylaxis in 2431 Hip and Knee Arthroplasty Patients: Primary Efficacy Outcomes and Safety Profile.
Highcock AJ; As-Sultany M; Finley R; Donnachie NJ
J Arthroplasty; 2020 Nov; 35(11):3093-3098. PubMed ID: 32674939
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulation in Pediatric Patients.
Male C
Hamostaseologie; 2022 Feb; 42(1):46-53. PubMed ID: 35042258
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation.
Shah S; Norby FL; Datta YH; Lutsey PL; MacLehose RF; Chen LY; Alonso A
Blood Adv; 2018 Feb; 2(3):200-209. PubMed ID: 29378726
[TBL] [Abstract][Full Text] [Related]
19. Real-world experience of direct oral anticoagulant use in a single pediatric center.
Valenti GG; Sabo C; Hyde M; Rajpurkar M
Pediatr Blood Cancer; 2024 May; 71(5):e30926. PubMed ID: 38449356
[TBL] [Abstract][Full Text] [Related]
20. Editor's Choice - Severe Bleeding Risks of Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism: A Network Meta-Analysis of Randomised Controlled Trials.
Chen J; Lv M; Wu S; Jiang S; Xu W; Qian J; Chen M; Fang Z; Zeng Z; Zhang J
Eur J Vasc Endovasc Surg; 2022 Mar; 63(3):465-474. PubMed ID: 34973879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
